Morgan Stanley Call 520 VRTX 21.0.../ DE000ME4N3N9 /
2024-05-21 9:21:03 AM | Chg.- | Bid8:00:25 AM | Ask8:00:25 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.033EUR | - | 0.032 Bid Size: 6,250 |
0.042 Ask Size: 6,250 |
Vertex Pharmaceutica... | 520.00 USD | 2024-06-21 | Call |
GlobeNewswire
05-15
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
05-08
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-08
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
05-07
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
04-30
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
04-27
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
04-22
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
04-22
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
04-09
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
GlobeNewswire
04-03
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
GlobeNewswire
04-01
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
04-01
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-13
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results